Category - Markets

Markets

Mackie starts Profound Medical at speculative buy

Mackie Research Capital initiated coverage of Profound Medical (TSX-V:PRN) with a “speculative buy” rating and 12-month target price of $3.30. The stock was quoted at $1.45 at mid-day on Wednesday. “Relative to all...

August 10, 2016

Markets

Maxim cuts Galena Biopharma price target to $1

Maxim Group lowered its price target for Galena Biopharma (NASDAQ:GALE) to $1 from $2, citing a shift in the company’s pipeline focus. The stock closed at 46 cents on Tuesday. At the end of June, an Independent Data...

August 10, 2016

Markets

Maxim cuts Omeros price target to $19

Maxim Group lowered its price target for Omeros (NASDAQ:OMER) to $19 from $30, citing a higher risk value from its three valuation models. The stock closed at $13.38 on Tuesday. Analyst Jason Kolbert writes that sales...

August 10, 2016

Markets

Maxim ups Sophiris price target to $6

Maxim Group raised it price target for Sophiris Bio (NASDAQ:SPHS) to $6 from $4, citing better data of the company’s topsalysin drug candidate. The stock closed at $5.04 on Tuesday. As the datasets for topsalysin...

August 10, 2016

Markets

Leerink upgrades Intellia Therapeutics to outperform

Leerink Partners upgraded Intellia Therapeutics (NASDAQ:NTLA) to “outperform” from “market perform” on valuation, with a price target of $32. The stock closed at $17.66 on Thursday. “We believe the current valuation...

August 5, 2016

Markets

Roth reinitiates coverage of Pieris Pharma at buy

Roth Capital Partners reinitiated coverage of Pieris Pharmaceuticals (NASDAQ:PIRS) with a “buy” rating and $6 price target. The stock closed at $1.70 on Thursday. “We believe the company’s anticalin platform has broad...

August 5, 2016

Markets

Maxim downgrades Radius Health to sell

Maxim Group downgraded Radius Health (NASDAQ:RDUS) to “sell” from “hold” with a $24 price target. The stock closed at $50.55 on Thursday. “At the current valuation, we believe that Radius is back to an overvalued...

August 4, 2016

Markets

WB downgrades EndoChoice to market perform

William Blair downgraded EndoChoice Holdings (NYSE:GI) to “market perform,” citing lower-than-expected second quarter results and reduced guidance. The stock closed at $5.26 on Wednesday. “While we continue to view...

August 4, 2016

Markets

Roth downgrades TearLab to neutral

Roth Capital Partners downgraded TearLab (NASDAQ:TEAR; TSX:TLB) to “neutral” from “buy,” citing sales transition challenges. The stock closed at 83 cents on Wednesday. Analyst Chris Lewis writes that TearLab’s second...

August 4, 2016

Markets

HCW cuts Galmed Pharma price target to $13

H.C. Wainwright lowered its price target to Galmed Pharmaceuticals (NASDAQ:GLMD) to $13 from $22, citing enrollment delays in a Phase 2b NASH trial of aramchol. The stock closed at $4.13 on Wednesday. “Given that Galmed...

August 4, 2016

Category - Markets

Subscribe